Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Blood lipid genetic scores, the HMGCR gene and cancer risk : A Mendelian randomization study

Author

  • Marju Orho-Melander
  • George Hindy
  • Signe Borgquist
  • Christina Alexandra Schulz
  • Jonas Manjer
  • Olle Melander
  • Tanja Stocks

Summary, in English

Background: It is unclear whether there are causal associations between blood lipids, statin use and cancer risks. Under certain assumptions, Mendelian randomization analysis of a genetic marker for an exposure eliminates reverse causation and confounding. Methods: We applied Mendelian randomization analysis to genetic scores, comprising 26–41 single-nucleotide polymorphisms (SNPs), as instrumental variables (IVs) for triglycerides and low- and high-density lipoprotein cholesterol (LDLC, HDLC), using a prospective cohort of 26 904 individuals in which there were 6607 incident cancers. We also investigated cancer risk for a SNP (rs12916) in the gene encoding hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the targeted enzyme in statin treatment. We used logistic regression and SNP pleiotropy-adjusted analyses to estimate the odds ratio per standard deviation (OR). Results: The OR for the triglyceride IV as a predictor of any cancer was 0.91 [95% confidence interval (CI): 0.80–1.03] unadjusted, and 0.87 (95% CI: 0.78–0.95) from the pleiotropy-adjusted analysis. For the HMGCR rs12916 per LDLC-lowering T-allele, the OR was 1.09 (95% CI: 1.01–1.18) for prostate cancer and 0.89 (95% CI: 0.82–0.96) for breast cancer. The LDLC IV was not associated with prostate cancer or breast cancer. There were no associations between IVs and cancers of the lung, colon or bladder. Conclusions: Under the assumptions of Mendelian randomization, there is a causal and negative association between serum triglycerides and risk of any cancer. Further, the HMGCR genetic variant might be associated with risks of prostate and breast cancers but the biological mechanisms behind these findings are unclear, as the LDLC IV was not associated with these cancers.

Department/s

  • Diabetes - Cardiovascular Disease
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health
  • Tumor microenvironment
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Surgery
  • Cardiovascular Research - Hypertension
  • Department of Clinical Sciences, Malmö
  • Register-based epidemiology

Publishing year

2018-04-01

Language

English

Pages

495-505

Publication/Series

International Journal of Epidemiology

Volume

47

Issue

2

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Medical Genetics
  • Cancer and Oncology

Keywords

  • Cohort studies
  • Lipoproteins
  • Mendelian randomization analysis
  • Neoplasms
  • Triglycerides

Status

Published

Research group

  • Diabetes - Cardiovascular Disease
  • Surgery
  • Cardiovascular Research - Hypertension
  • Register-based epidemiology

ISBN/ISSN/Other

  • ISSN: 0300-5771